FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2308706242> ?p ?o ?g. }

• W2308706242 endingPage "e009849" @default.
• W2308706242 startingPage "e009849" @default.
• W2308706242 abstract "<h3>Introduction</h3> Concurrent ONce-daily VErsus twice-daily RadioTherapy (CONVERT) is the only multicentre, international, randomised, phase III trial open in Europe and Canada looking at optimisation of chemoradiotherapy (RT) in limited stage small cell lung cancer (LS-SCLC). Following on from the Turrisi trial of once-daily versus twice-daily (BD) concurrent chemoradiotherapy, there is a real need for a new phase III trial using modern conformal RT techniques and investigating higher once-daily radiation dose. This trial has the potential to define a new standard chemo-RT regimen for patients with LS-SCLC and good performance status. <h3>Methods and analysis</h3> 447 patients with histologically or cytologically proven diagnosis of SCLC were recruited from 74 centres in eight countries between 2008 and 2013. Patients were randomised to receive either concurrent twice-daily RT(45 Gy in 30 twice-daily fractions over 3 weeks) or concurrent once-daily RT(66 Gy in 33 once-daily fractions over 6.5 weeks) both starting on day 22 of cycle 1. Patients are followed up until death. The primary end point of the study is overall survival and secondary end points include local progression-free survival, metastasis-free survival, acute and late toxicity based on the Common Terminology Criteria for Adverse Events V.3.0, chemotherapy and RTdose intensity. <h3>Ethics and dissemination</h3> The trial received ethical approval from NRES Committee North West—Greater Manchester Central (07/H1008/229). There is a trial steering committee, including independent members and an independent data monitoring committee. Results will be published in a peer-reviewed journal and presented at international conferences. <h3>Trial registration number</h3> ISRCTN91927162; Pre-results." @default.
• W2308706242 created "2016-06-24" @default.
• W2308706242 creator A5007868555 @default.
• W2308706242 creator A5025124724 @default.
• W2308706242 creator A5025279015 @default.
• W2308706242 creator A5039103158 @default.
• W2308706242 creator A5040285878 @default.
• W2308706242 creator A5055205671 @default.
• W2308706242 creator A5060124792 @default.
• W2308706242 creator A5064837893 @default.
• W2308706242 creator A5068141709 @default.
• W2308706242 creator A5069095893 @default.
• W2308706242 creator A5077087948 @default.
• W2308706242 creator A5089954905 @default.
• W2308706242 date "2016-01-01" @default.
• W2308706242 modified "2023-10-02" @default.
• W2308706242 title "Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status" @default.
• W2308706242 cites W1827086524 @default.
• W2308706242 cites W1885320430 @default.
• W2308706242 cites W1905406155 @default.
• W2308706242 cites W1920090590 @default.
• W2308706242 cites W1973510243 @default.
• W2308706242 cites W1992291788 @default.
• W2308706242 cites W2020917220 @default.
• W2308706242 cites W2049116330 @default.
• W2308706242 cites W2119063943 @default.
• W2308706242 cites W2141539943 @default.
• W2308706242 cites W2150713507 @default.
• W2308706242 cites W2323020638 @default.
• W2308706242 cites W2341745217 @default.
• W2308706242 doi "https://doi.org/10.1136/bmjopen-2015-009849" @default.
• W2308706242 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4735219" @default.
• W2308706242 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26792218" @default.
• W2308706242 hasPublicationYear "2016" @default.
• W2308706242 type Work @default.
• W2308706242 sameAs 2308706242 @default.
• W2308706242 citedByCount "32" @default.
• W2308706242 countsByYear W23087062422015 @default.
• W2308706242 countsByYear W23087062422016 @default.
• W2308706242 countsByYear W23087062422017 @default.
• W2308706242 countsByYear W23087062422018 @default.
• W2308706242 countsByYear W23087062422019 @default.
• W2308706242 countsByYear W23087062422020 @default.
• W2308706242 countsByYear W23087062422021 @default.
• W2308706242 countsByYear W23087062422023 @default.
• W2308706242 crossrefType "journal-article" @default.
• W2308706242 hasAuthorship W2308706242A5007868555 @default.
• W2308706242 hasAuthorship W2308706242A5025124724 @default.
• W2308706242 hasAuthorship W2308706242A5025279015 @default.
• W2308706242 hasAuthorship W2308706242A5039103158 @default.
• W2308706242 hasAuthorship W2308706242A5040285878 @default.
• W2308706242 hasAuthorship W2308706242A5055205671 @default.
• W2308706242 hasAuthorship W2308706242A5060124792 @default.
• W2308706242 hasAuthorship W2308706242A5064837893 @default.
• W2308706242 hasAuthorship W2308706242A5068141709 @default.
• W2308706242 hasAuthorship W2308706242A5069095893 @default.
• W2308706242 hasAuthorship W2308706242A5077087948 @default.
• W2308706242 hasAuthorship W2308706242A5089954905 @default.
• W2308706242 hasBestOaLocation W23087062421 @default.
• W2308706242 hasConcept C126322002 @default.
• W2308706242 hasConcept C141071460 @default.
• W2308706242 hasConcept C143998085 @default.
• W2308706242 hasConcept C168563851 @default.
• W2308706242 hasConcept C1862650 @default.
• W2308706242 hasConcept C197934379 @default.
• W2308706242 hasConcept C203092338 @default.
• W2308706242 hasConcept C2777793932 @default.
• W2308706242 hasConcept C2778424827 @default.
• W2308706242 hasConcept C2781413609 @default.
• W2308706242 hasConcept C509974204 @default.
• W2308706242 hasConcept C535046627 @default.
• W2308706242 hasConcept C71924100 @default.
• W2308706242 hasConcept C73751289 @default.
• W2308706242 hasConcept C79544238 @default.
• W2308706242 hasConceptScore W2308706242C126322002 @default.
• W2308706242 hasConceptScore W2308706242C141071460 @default.
• W2308706242 hasConceptScore W2308706242C143998085 @default.
• W2308706242 hasConceptScore W2308706242C168563851 @default.
• W2308706242 hasConceptScore W2308706242C1862650 @default.
• W2308706242 hasConceptScore W2308706242C197934379 @default.
• W2308706242 hasConceptScore W2308706242C203092338 @default.
• W2308706242 hasConceptScore W2308706242C2777793932 @default.
• W2308706242 hasConceptScore W2308706242C2778424827 @default.
• W2308706242 hasConceptScore W2308706242C2781413609 @default.
• W2308706242 hasConceptScore W2308706242C509974204 @default.
• W2308706242 hasConceptScore W2308706242C535046627 @default.
• W2308706242 hasConceptScore W2308706242C71924100 @default.
• W2308706242 hasConceptScore W2308706242C73751289 @default.
• W2308706242 hasConceptScore W2308706242C79544238 @default.
• W2308706242 hasIssue "1" @default.
• W2308706242 hasLocation W23087062421 @default.
• W2308706242 hasLocation W23087062422 @default.
• W2308706242 hasLocation W23087062423 @default.
• W2308706242 hasOpenAccess W2308706242 @default.
• W2308706242 hasPrimaryLocation W23087062421 @default.
• W2308706242 hasRelatedWork W1132082835 @default.
• W2308706242 hasRelatedWork W1694442327 @default.
• W2308706242 hasRelatedWork W2068669225 @default.

• next